TSI (Thyroid Stimulating Immunoglobulin)

This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

SRHC Clients:

• 1 yellow top tube or 1 red top tube
• Store and transport  serum refrigerated
• Transport to SRHC laboratory same day as collected
• Room temperature unacceptable

LAB746

30551

1 mL serum

0.2 mL

Refrigerated (cold packs)

Room temperature: Unacceptable
Refrigerated: 21 days
Frozen: 60 days

Gross hemolysis • Grossly lipemic • Grossly icteric • Plasma

Set up: Mon-Sat; Report available: 3-5 days

<140 % Baseline

Graves' disease is a classic form of hyperthyroid disease, affecting approximately 0.4% of the population of the United States. It is caused by IgG immunoglobulins, collectively known as thyroid stimulating immunoglobulins (TSI). Patients who are candidates for antithyroid drug therapy may not respond to this treatment when TSI levels are markedly elevated. The determination of TSI can also assist in predicting hyperthyroidism in neonates, due to placental transmission of the immunoglobulins from a mother with hyperthyroidism.